Search results for "malattie"

showing 10 items of 1963 documents

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

2020

Contains fulltext : 218279.pdf (Publisher’s version ) (Open Access) Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (>/=0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 …

OncologyPROBABILITIESMalePROGNOSISCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]NPM1 MUTATIONBiochemistryEuropean LeukemiaNetchemistry.chemical_compoundALLELIC RATIOAMLRisk FactorsGene Duplicationhemic and lymphatic diseasesMidostaurinFLT3Myeloid NeoplasiaHematopoietic Stem Cell TransplantationMyeloid leukemiaNuclear ProteinsHematologyCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenEuropeLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeTandem Repeat SequencesFemaleNucleophosminmedicine.medical_specialtyNPM1GenotypeImmunologyYOUNGER ADULTSInternal medicineWhite blood cellmedicineNORMAL CYTOGENETICSHumansGenetic Predisposition to DiseaseProportional Hazards ModelsProportional hazards modelbusiness.industryCell BiologyINTERNAL TANDEM DUPLICATIONTransplantationchemistryfms-Like Tyrosine Kinase 3Multivariate AnalysisbusinessSettore MED/15 - Malattie del Sangue
researchProduct

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment

2010

The importance of adoption of recommendations for ONJ prevention strategy will notably grow for zoledronic acid in the next future, in view of possible further enlargement of its indications (even with different timing and schedules) in breast cancer patients without bone metastases (such as in adjuvant and neo-adjuvant settings, and in hormonotherapy-induced osteopenia

Oncologymedicine.medical_specialtyBreast Neoplasmszoledronic acidBreast cancerSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansBone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawbusiness.industryImidazolesOsteonecrosisGeneral Medicinemedicine.diseaseosteonecrosis jawsZoledronic acidJawbreast cancer patientsFemaleSurgerybusinessOsteonecrosis of the jawmedicine.drugThe Breast
researchProduct

Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years.

2009

Abstract Abstract 2910 Poster Board II-886 Background: Polycythemia vera (PV) and primary myelofibrosis (PMF) are stem cell-derived myeloproliferative neoplasms characterized clinically by increased red cell volume and bone marrow fibrosis, respectively. Phlebotomy is the cornerstone of treatment in PV whereas hydroxyurea has been the traditional drug of choice in both PV and PMF. Over the last 20 years, several new treatment approaches have been introduced and promoted (e.g. interferon-alpha, anagrelide, thalidomide, allogeneic stem cell transplantation) but their benefit in terms of survival has not been confirmed in controlled studies. Methods: Study patients were recruited form the Mayo…

Oncologymedicine.medical_specialtyPediatricsbusiness.industryProportional hazards modelImmunologyCell BiologyHematologyAnagrelidemedicine.diseaseBiochemistrySettore MED/15 - Malattie Del Sanguemyelofibrosis survivalTransplantationLog-rank testPolycythemia veraInternational Prognostic Scoring SystemInternal medicinemedicinebusinessMyelofibrosisSurvival analysismedicine.drugBlood
researchProduct

Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literatu…

2021

Ruxolitinib side effects include the most frequent hematological toxicity along with a more recently evidenced immunosuppressive activity, interfering both with the innate and adaptive immunity, and several cases of reactivation of latent infections by opportunistic agents in patients in treatment with ruxolitinib have been published in the last years. Several pathophysiological mechanisms may explain an association between ruxolitinib and opportunistic infections. From what we know, the only case of an isolated lymph node TBC reactivation in a ruxolitinib-treated myelofibrosis (MF) patient was reported by Patil et al. in 2016 [Int J Med Sci Public Health. 2017;6(3):1]. Other 10 cases descr…

Oncologymedicine.medical_specialtyRuxolitinibConstitutional symptomsSettore MED/15 - Malattie Del SangueHematological toxicityInternal medicineDrug DiscoverymedicinePharmacology (medical)In patientMyelofibrosisProspective cohort studyLymph nodePharmacologybusiness.industryInfection Myelofibrosis Reactivation Tuberculosis Ruxolitinib TBCGeneral Medicinemedicine.diseaseInfectious Diseasesmedicine.anatomical_structureOncologySputummedicine.symptombusinessmedicine.drug
researchProduct

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma pat…

2021

The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared with EloRd cohort. Moreover, cytogenetic risk categori…

Oncologymedicine.medical_specialtySalvage therapyAntibodies Monoclonal HumanizedDexamethasoneSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansElotuzumabLenalidomideDexamethasoneMultiple myelomaLenalidomideRetrospective StudiesSalvage Therapycarfilzomibbusiness.industryHazard ratioHematologyGeneral Medicinemedicine.diseaseCarfilzomibelotuzumabmultiple myelomachemistryCohortbusinessOligopeptidesmedicine.drug
researchProduct

Vulvar cancer: a review for dermatologists.

2015

Vulvar malignancies are important tumors of the female reproductive system. They represent a serious health issue with an incidence between 2 and 7 per 100,000 and year. We provide a review about most important cancer entities, i.e., melanoma, squamous cell carcinoma, basal cell carcinoma, neuroendocrine cancer, and skin adnexal malignancies. Squamous cell carcinoma is the most common vulvar malignancy that can develop from vulvar intraepithelial neoplasia or de novo. Basal cell carcinoma represents only 2 % of all vulvar cancers. Melanoma of the vulva exists in two major types—superficial spreading and acral lentiginous. A special feature is the occurrence of multiple vulvar melanomas. Of …

Oncologymedicine.medical_specialtySkin NeoplasmsMalignancyVulvaVulvaDiagnosis DifferentialVulva · Squamous cell carcinoma · Basal cell carcinoma · Melanoma · Paget’s disease · Adnexal carcinomasInternal medicineCarcinomamedicineSettore MED/35 - Malattie Cutanee E VenereeHumansBasal cell carcinomaMelanomaNeoplasm StagingSkinintegumentary systemVulvar Neoplasmsurogenital systembusiness.industryMelanomaCancerGeneral MedicineVulvar cancermedicine.diseaseVulvar intraepithelial neoplasiaPrognosisDermatologyfemale genital diseases and pregnancy complicationsNeuroendocrine Tumorsmedicine.anatomical_structurePaget Disease ExtramammaryCarcinoma Basal CellCarcinoma Squamous CellFemaleNeoplasms Adnexal and Skin AppendagebusinessCarcinoma in SituWiener medizinische Wochenschrift (1946)
researchProduct

Lung cancer: does age affect treatment strategy?

2009

Oncologymedicine.medical_specialtybusiness.industryInternal medicinemedicineTreatment strategyLung cancer elderlySettore MED/10 - Malattie Dell'Apparato RespiratoriobusinessAffect (psychology)Lung cancermedicine.disease
researchProduct

Long Term Results of Stanford V Regimen and Highly Active Antiretroviral Therapy (HAART) In 59 Patients (pts) with HD and HIV Infection (HD-HIV)

2010

Abstract Abstract 4827 Background: The introduction of HAART has significantly improved the outcome of pts with HD-HIV. However there are no data on the long term follow-up of HD-HIV pts treated with conventional chemotherapy (CT) regimens. In 2002, we reported the results of a prospective phase II study with the intensive 12-week CT with adjuvant radiotherapy (Stanford V) and concomitant HAART in 59 pts (Spina et al. Blood 2002;100:1984-1988). Methods: To analyze the long term outcome of patients included in the Stanford V and HAART protocol. Results: The median follow-up is 67months (range 3–156 months The 5-yr overall survival (OS), freedom from progression (FFP), disease free survival a…

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyHuman immunodeficiency virus (HIV)Phases of clinical researchCell BiologyHematologyStanford V regimenLong term resultschemotherapymedicine.disease_causemedicine.diseaseBiochemistrySettore MED/15 - Malattie Del SangueSurgeryStanford VIdiopathic pneumonia syndromeInternal medicineConcomitantmedicineHodgkin's diseaseFresh frozen plasmabusinessBlood
researchProduct

A return to humane medicine: Osler's legacy.

2017

Sir William Osler is celebrated today not only for his contributions to the advancement of medical education, but also for the humanism he brought to the practice of medicine. He was a doctor whose bedside skills and manners were emulated, and can legitimately be called an infectious diseases specialist. Nonetheless, he was also a humanist in the broader sense of the term, a student of human affairs and human nature, who emphasised compassion for the individual. To what extent, if any, are today's challenges influenced by departures from the paradigms created by Osler? In this paper we sought to ascertain whether such a tradition is still relevant to current practice and may foster a new pe…

OntarioInfectious Disease MedicinePhysician-Patient RelationsEducation MedicalHumanities Formazione medica Relazione medico-paziente Osler Empatia Medicina Interna Malattie infettiveAttitude of Health PersonnelHistory 19th CenturyHistory 20th CenturySettore MED/43 - MEDICINA LEGALEHumane Medicine Humanities Medical Education Patient-physician relationship Osler Empathy Internal Medicine Infectious diseasesUnited StatesSettore MED/02 - STORIA DELLA MEDICINAPhysiciansHumanismInternal MedicineOsler's legacyHumansHistory of MedicinePractice Patterns Physicians'Medicina umanaMedical Humanities
researchProduct

Thinking about ophthalmology in the era of the COVID-19 pandemic

2020

There is no part of the health care system that has remained unscathed by the COVID-19 pandemic in terms of its organizational, scientific or medical models. The surgical specialities were called upon to analyse the concepts of urgency and deferrable, reconsider the procedures and the times for those, and to evaluate new and specific strategies for the remote and safe management of patients. The aim of this paper is to evaluate new and different approaches in the field of ophthalmology triggered by the COVID-19 emergency. We analysed literature and on line documents; key words for the research were: SARS-CoV-2, COVID-19, ophthalmology, ophthalmologist, eye, guidelines, and their combination…

OphthalmologyPandemicSARS-CoV-2Settore MED/30 - Malattie Apparato VisivoCOVID-19
researchProduct